Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has appointed Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, including roles at Bristol Myers Squibb, Karuna Therapeutics and AbbVie. His expertise is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
This appointment comes as Helus Pharma progresses its lead candidate, HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Helus also maintains an extensive research portfolio of investigational NSAs.
Dr. Kramer's experience includes leading medical affairs strategies for neuroscience products at major pharmaceutical companies. At Bristol Myers Squibb, he oversaw medical affairs for the company's psychiatry portfolio, and at Karuna Therapeutics, he contributed to the development of treatments for central nervous system disorders. His background aligns with Helus's mission to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions through novel serotonergic agonists that aim to promote neuroplasticity and provide durable improvements in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is committed to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways. The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit the company's newsroom at https://ibn.fm/HELP.
The addition of Dr. Kramer underscores Helus's focus on strengthening its medical affairs capabilities as it advances its pipeline toward potential regulatory approvals. With class-leading data, the company aims to improve the treatment landscape for mental health conditions through its innovative NSA platform.
